期刊文献+

临床药师参与439例神经科感染性疾病会诊分析 被引量:6

Analysis of 439 Cases of Infection Diseases from Neurology Ward Consulted by Clinical Pharmacists
下载PDF
导出
摘要 目的:分析神经科感染性疾病的特点,为临床治疗提供参考。方法:对某院2011-2013年神经科感染患者的临床药师会诊记录单进行回顾性分析。结果:在439例会诊病例中,65岁以上的老年人256例(58.31%);主要为肺部感染294例(65.33%)、泌尿道感染40例(8.89%)、颅内感染37例(8.22%);经培养共分离病原菌510株,其中革兰阴性杆菌362株(70.98%),革兰阳性球菌127株(24.90%),真菌21株(4.12%),排名前5位的病原菌依次是铜绿假单胞菌125株(24.51%)、鲍曼不动杆菌93株(18.24%)、肺炎克雷伯菌88株(17.25%)、金黄色葡萄球菌68株(13.33%)、大肠埃希菌32株(6.27%);肠杆菌科细菌中肺炎克雷伯菌、大肠埃希菌产ESBLs分别为61.36%和75.00%,铜绿假单胞菌对美罗培南、亚胺培南的敏感率分别为65.8%、70.6%,鲍曼不动杆菌耐药严重,其中泛耐药菌21株(22.58%),革兰阳性球菌对万古霉素和替考拉宁高度敏感,金黄色葡萄球菌中耐甲氧西林耐药株(MRSA)的检出率为52.24%;会诊意见被医师全部采纳的有372例(84.74%),部分采纳的有32例(7.28%),未采纳的有35例(7.97%);会诊意见全部采纳和部分采纳的病例中有效的有319例(78.96%);将采纳情况和预后情况进行双向有序线性趋势检验,线性回归分量有统计学意义(P〈0.01),等级相关系数为0.325(P〈0.01),该资料说明预后随着采纳情况增加而变好。结论:临床药师在神经科参与感染性疾病治疗,特别是耐药菌的治疗中,提高了有效率,发挥着重要作用。 Objective: To analyze the characteristics of infectious diseases from neurology ward and provide reference for the treatment. Methods: The consultation record of the neurological patients who suffered infection diseases were retrospectively summarized from January 2011 to December 2013. All the consultation were performed by clinical pharmacists. SPSS 19. 0 software was used to analyze the adoption and prognosis of the outcomes. Results: In 439 consultation cases,256 patients( 58. 31%) were older than 65 years. Most of the cases were respiratory infection( 294 cases,65. 33%),urinary tract infection( 40 cases,8. 89%) and intracranial infection( 37 cases,8. 22%). There were 510 strains of bacteria isolated by culturing,in which 362 strains were gram-negative bacteria( 70. 98%),127 strains were gram-positive bacteria( 24. 90%) and 21 strains were fungi( 4. 12%). The top five of pathogenic bacteria were Pseudomonas aeruginosa( 125 stains,24. 51%),Acinetobacter baumannii( 93 stains,18. 24%),Staphylococcus aureus( 88 stains,17. 25%),Staphylococcus aureus( 68 stains,13. 33%) and Escherichia coli.( 32 stains,6. 27%). The detection rates of ESBLs of K. pneumonia and E. coli were 61. 36% and 75. 00%,respectively. Among 125 strains of P. aeruginosa,the sensitive rate to meropenem and inipenem was 65. 8% and 70. 6%,respectively. A. baumannii was highly multidrug resistant,and 21 strains( 22. 58%) with pan-drug resistance were isolated. Gram-positive bacteria were highly sensitive to vancomycin and teicoplanin. Totally35 strains( 52. 24%) of MRSA were isolated. The complete adoption rate of consultation opinion was 84. 74%( 372 cases),the partial adoption rate was 7. 28%( 32 cases),and 35 cases( 7. 97%) were declined. In all the adopted cases( 319 cases,78. 96%) showed effectiveness. In the linear correlation analysis,the consultation adoption and therapy outcomes had significant correlation( P〈0. 01).Conclusion: Clinical pharmacists can improve the efficiency in anti-infection therapy and play important roles in the treatment of infectious diseases in neurology ward,especially in the treatment of drug-resistant bacterial infections.
出处 《中国药师》 CAS 2015年第4期624-627,共4页 China Pharmacist
基金 湖南省中医药管理局科技计划基金资助项目(编号:2013146)
关键词 临床药师 神经科 抗感染 会诊 Clinical pharmacist Department of neurology Anti-infection therapy Consultation
  • 相关文献

参考文献13

二级参考文献142

共引文献674

同被引文献68

  • 1DagerwE,GulsethMP,NuteseuEA.抗凝治疗医护指南[M].师少军,吕永宁译.北京:人民卫生出版社,2012:6,11.
  • 2ELEWA H, JALALI F, KHUDAIR N, et al. Evaluation of pharma- cist - based compared to doctor - based anticoagulation management in Qatar [ J ]. J EvalClinPract, 2016,22 (3) :433 - 438.
  • 3PHILLIPS K W, WITTKOWSKY A K. Survey of pharmacist -managed inpatient anticoagulation services [ J ]. Am J Health Syst Pharm, 2007, 64( 21 ):2275- 2278.
  • 4GORDON H, ELIE A, MARK CROWTHER, et al. Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence - based clinical practice guidelines[J].Chest, 2012,141 (2 Suppl) :$7 - $47.
  • 5JOHN W, JACK HIRSH, FREDERICK A, et al. Antiplatelet drugs: Antithrombotic therapy and prevention of thrombosis, 9th ed : American college of chest physicians evidence - based clinical practice guidelines [J]. Chest, 2012,141(2) (Suppl) :$89 -Sl19.
  • 6JOHNSON J A, GONG L, WHIRL - CARRILLO M, et al. Clinical pharmaeogeneties implementation consortium guidelines for CYtr2C9 and VKORC1 genotypes and warfarin dosing. Clinical pharmacology ami therapeutics[ J ]. Clin Pharmacol Ther, 2011,90 ( 4 ) : 625 - 629.
  • 7SCOTR S A, SANGKUHL K, STEIN C M, et al. Clinical pharma- cogenetics implementation consortium guidelines for CYP2C19 geno- type and clopidogrel therapy: 2013 update [ J ]. Clin Pharma~ol Ther, 2013,94(3) :317 -323.
  • 8WALLENTIN L, BECKER R C, BUDAJ A, et al. Ticagrelor ver- sus Clopidogrel in Patients with Acute Coronary Syndromes[ J]. N Engl J Med, 2009,361 ( 11 ) :1045 - 1057.
  • 9严勇,于明琨.神经外科术后颅内感染危险因素分析[J].中华神经外科杂志,2008,24(11):862-863. 被引量:26
  • 10官真水,周孝桃.临床药师参与227例抗菌药物应用会诊情况分析与思考[J].中国药房,2009,20(17):1358-1360. 被引量:11

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部